Free Trial
NASDAQ:GLUE

Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Monte Rosa Therapeutics logo
$4.38 +0.15 (+3.55%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$4.38 0.00 (-0.11%)
As of 08/8/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Key Stats

Today's Range
$4.12
$4.40
50-Day Range
$4.23
$5.96
52-Week Range
$3.50
$12.40
Volume
404,889 shs
Average Volume
449,362 shs
Market Capitalization
$269.41 million
P/E Ratio
12.17
Dividend Yield
N/A
Price Target
$15.33
Consensus Rating
Moderate Buy

Company Overview

Monte Rosa Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

GLUE MarketRank™: 

Monte Rosa Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 511th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Monte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Monte Rosa Therapeutics has received no research coverage in the past 90 days.

  • Read more about Monte Rosa Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monte Rosa Therapeutics is 12.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.91.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monte Rosa Therapeutics is 12.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.01.

  • Price to Book Value per Share Ratio

    Monte Rosa Therapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Monte Rosa Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    19.40% of the float of Monte Rosa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Monte Rosa Therapeutics has recently increased by 0.68%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Monte Rosa Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Monte Rosa Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.40% of the float of Monte Rosa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Monte Rosa Therapeutics has recently increased by 0.68%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Monte Rosa Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Monte Rosa Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for GLUE on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Monte Rosa Therapeutics is held by insiders.

  • Percentage Held by Institutions

    79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Monte Rosa Therapeutics' insider trading history.
Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GLUE Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

GLUE Stock Analysis - Frequently Asked Questions

Monte Rosa Therapeutics' stock was trading at $6.94 at the start of the year. Since then, GLUE stock has decreased by 36.9% and is now trading at $4.38.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its earnings results on Thursday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.16. The company had revenue of $23.19 million for the quarter, compared to the consensus estimate of $7.23 million. Monte Rosa Therapeutics had a net margin of 13.58% and a trailing twelve-month return on equity of 10.31%.

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share.

Top institutional investors of Monte Rosa Therapeutics include Geode Capital Management LLC (1.83%), Intech Investment Management LLC (0.05%), CWM LLC (0.05%) and Bailard Inc. (0.04%). Insiders that own company stock include Versant Venture Capital Vi, L, Edmund Dunn and Chandra P Leo.
View institutional ownership trends
.

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/07/2025
Today
8/09/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLUE
CIK
1826457
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$19.00
Low Price Target
$10.00
Potential Upside/Downside
+250.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.08
Trailing P/E Ratio
12.17
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$72.70 million
Net Margins
13.58%
Pretax Margin
5.93%
Return on Equity
10.31%
Return on Assets
6.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.61
Quick Ratio
5.61

Sales & Book Value

Annual Sales
$75.62 million
Price / Sales
3.56
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.63 per share
Price / Book
1.21

Miscellaneous

Outstanding Shares
61,510,000
Free Float
57,266,000
Market Cap
$269.41 million
Optionable
Optionable
Beta
1.42
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:GLUE) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners